Viewing Study NCT00002348



Ignite Creation Date: 2024-05-05 @ 10:17 AM
Last Modification Date: 2024-10-26 @ 9:03 AM
Study NCT ID: NCT00002348
Status: COMPLETED
Last Update Posted: 2020-12-19
First Post: 1999-11-02

Brief Title: A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkins Lymphoma
Sponsor: Genzyme a Sanofi Company
Organization: Sanofi

Study Overview

Official Title: Phase II Evaluation of Mitoguazone Dihydrochloride in Patients With Refractory or Relapsed Non-Hodgkins Lymphoma Associated With Acquired Immunodeficiency Syndrome
Status: COMPLETED
Status Verified Date: 1996-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To estimate the response rate response duration clinical benefit and toxicity of mitoguazone dihydrochloride MGBG in patients with AIDS-related refractory or relapsing non-Hodgkins lymphoma NHL
Detailed Description: Patients receive infusions of MGBG on days 1 and 8 and every 2 weeks thereafter It is suggested that a lumbar puncture be performed to evaluate for leptomeningeal disease

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
IDD-007 None None None